Atara Biotherapeutics, Inc.
No SEC Form 4 filings for $ATRA in the last 30 days.
See all $ATRA insider activity →Atara Biotherapeutics (ATRA) is scheduled to report Q3'26 earnings on October 29. Analysts expect revenue of 800,000 USD and an EPS of -0.13 USD. The announcement is expected at 8:00 AM ET.
Atara Biotherapeutics (ATRA) announced the FDA accepted its resubmitted BLA for tabelecleucel, setting a PDUFA target date of Mar 31, 2027. Approval could result in a $31.0M milestone payment from Pierre Fabre. This follows earlier regulatory setbacks and sets a clear U.S. review timeline.
NewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ATRA (Atara Biotherapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ATRA coverage spans financial news, earnings and corporate actions.
The disclosed guidance may pressure the stock if results miss expectations.
Regulatory acceptance moves the product toward potential approval and a $31M milestone, likely supporting the stock.
BLA resubmission may accelerate FDA review and future sales.
Regulatory re‑filing may revive the drug's approval prospects.
Regulatory timeline extension may delay near‑term upside but keeps the program alive.
AlphAI scores every news story that mentions ATRA with an AI model for sentiment and relevance, and aggregates insider trades from Atara Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Atara Biotherapeutics (ATRA) is scheduled to report Q3'26 earnings on October 29. Analysts expect revenue of 800,000 USD and an EPS of -0.13 USD. The announcement is expected at 8:00 AM ET.
1 min readAtara Biotherapeutics (ATRA) announced the FDA accepted its resubmitted BLA for tabelecleucel, setting a PDUFA target date of Mar 31, 2027. Approval could result in a $31.0M milestone payment from Pierre Fabre. This follows earlier regulatory setbacks and sets a clear U.S. review timeline.
2 min readNewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.
2 min readModerna appointed Juan Andres as its new COO to support expansion into oncology. Pierre Fabre and Atara refiled Ebvallo for FDA approval to treat a rare blood cancer. Beam Therapeutics sued a Chinese company, alleging IP theft by a former scientist.
2 min readBluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.
3 min readEnovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.
3 min readCherry Brian N purchased 104,166 shares of Atara Biotherapeutics, Inc. (ATRA) at $9.60 ($1.00M total) on 2026-09-04.
1 min readAtara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress Productive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87%
6 min readAtara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001604464 false 0001604464 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,
3 min readAtara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001604464 0001604464 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min read
